VLS

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Wednesday, April 10, 2024
Hypertelorism, DLT, Safety, Radiation, Pancreatic cancer, TSX, PR, Cancer, LFT, Regulatory T cell, Patient, MDNA, RDE, Duodenal cancer, Toxicity, Melanoma, BCC, MCC, AACR, VLS, MSI-H, PD, NK, Combination therapy, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

HII is Awarded $74 Million Contract to Support U.S. Navy Vertical Launch Systems

Retrieved on: 
Tuesday, April 9, 2024
VLS, HII, Science, Research, Naval Surface Warfare Center, MAC, IAC, NSWC, DDG, Defense Technical Information Center, Mission, Mk, Engineering, Navy

HII’s statement of work includes outfitting the first Zumwalt-class destroyer (DDG 1001) with the latest Mk 57 vertical launch system universal canister electronics unit.

Key Points: 
  • HII’s statement of work includes outfitting the first Zumwalt-class destroyer (DDG 1001) with the latest Mk 57 vertical launch system universal canister electronics unit.
  • “We are extremely pleased to continue our support to the U.S. Navy, providing critical research, development, test and evaluation in support of vertical launch systems for NSWC Port Hueneme,” said Todd Gentry, president of Mission Technologies’ C5ISR business group.
  • HII was awarded the recompeted task order under the Department of Defense’s Information Analysis Center Multiple Award Contract vehicle (IAC MAC).
  • HII’s support to NSWC Port Hueneme is an extension of work performed under a previous contract awarded in 2021.

LJP Waste Solutions Announces Michael Malatesta as its new Chief Executive Officer

Retrieved on: 
Thursday, April 4, 2024
Finance, Environment, Recycling, Professional Services, Sustainability, LJP, VLS, Waste management, Growth, GRN, Sale, Acquisition, DBA, Ecosystem, Covanta, Malatesta, Management

LJP Waste Solutions , a leading provider of zero landfill and traditional waste management services, announced the appointment of Michael Malatesta as its new Chief Executive Officer, effective April 2, 2024.

Key Points: 
  • LJP Waste Solutions , a leading provider of zero landfill and traditional waste management services, announced the appointment of Michael Malatesta as its new Chief Executive Officer, effective April 2, 2024.
  • Retiring CEO Steve Metz will remain on the LJP board and support key organic and inorganic growth initiatives.
  • I look forward to joining the LJP team and advancing our strategic initiatives,” said CEO Mike Malatesta.
  • Mr. Malatesta was introduced to LJP Waste Solutions by Tyler Frisbie , the President of executive search firm Frisbie Search Partners, Inc. DBA - GRN McKinney.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Retrieved on: 
Thursday, November 23, 2023
Urea, Quality of life, Protein, Woman, Chronic kidney disease, Pain, CMO, Lichen, Itch, Health, Therapy, POC, Inflammation, Skin, PAD, Dicarboxylic acid, Fissure, MC2, VLS, Patient, Safety, Pharmaceutical industry

MC2-25 VLS is a novel treatment paradigm based on a di-peptide that inhibits carbamylation of amino acids and proteins in skin.

Key Points: 
  • MC2-25 VLS is a novel treatment paradigm based on a di-peptide that inhibits carbamylation of amino acids and proteins in skin.
  • MC2 Therapeutics believes that carbamylation of amino acids and proteins in the vulvar region by iso-cyanate is the root cause of VLS.
  • The Phase 2 clinical trial is being conducted at multiple centres across Denmark and will evaluate the safety and efficacy of MC2-25 VLS in patients with VLS.
  • The data generated from this double-blinded, placebo-controlled PoC trial will inform the trial design for a larger Phase 2b trial.

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Retrieved on: 
Thursday, November 23, 2023
Urea, Quality of life, Protein, Woman, Chronic kidney disease, Pain, CMO, Lichen, Itch, Health, Therapy, POC, Inflammation, Skin, PAD, Dicarboxylic acid, Fissure, MC2, VLS, Patient, Safety, Pharmaceutical industry

MC2-25 VLS is a novel treatment paradigm based on a di-peptide that inhibits carbamylation of amino acids and proteins in skin.

Key Points: 
  • MC2-25 VLS is a novel treatment paradigm based on a di-peptide that inhibits carbamylation of amino acids and proteins in skin.
  • MC2 Therapeutics believes that carbamylation of amino acids and proteins in the vulvar region by iso-cyanate is the root cause of VLS.
  • The Phase 2 clinical trial is being conducted at multiple centres across Denmark and will evaluate the safety and efficacy of MC2-25 VLS in patients with VLS.
  • The data generated from this double-blinded, placebo-controlled PoC trial will inform the trial design for a larger Phase 2b trial.

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, November 6, 2023
Hypertelorism, PD, VLS, Trae tha Truth, BCC, MSI-H, MDNA, MCC, Poster, Pharmacodynamics, SITC, Immunotherapy, Radiation, SD, RDE, PK, DLT, Safety, Society, CSCC, PDAC, Patient, Combination therapy, Toxicity, TSX, LFT, Nevus, Medical imaging, Pharmaceutical industry, Vaccine

MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.

Key Points: 
  • MDNA11 with uniquely differentiating ‘beta-enhanced not-alpha’ features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors.
  • Following return from a 7 week vacation, a single new lesion was observed and MDNA11 treatment was resumed.
  • Monotherapy expansion part of ABILITY-1 is enrolling patients with metastatic melanoma, non-melanoma skin cancers (CSCC, MCC, and BCC) and MSI-H/dMMR tumors.
  • A copy of the poster and a related slide deck have been posted to the “ Events and Presentations ” page of Medicenna’s website.

Rubicon VLS and Logility Turbocharge Network Design and Optimization for Stellantis

Retrieved on: 
Wednesday, June 21, 2023
Technology, Automotive, General Automotive, Software, Internet, Retail, Supply Chain Management, Artificial Intelligence, Online Retail, Software as a service, Digital supply chain security, ICL, Peugeot, Dodge, Fiat, Carbon, Ship, VLS, ESG, Rubicon, Transport, Chrysler, Jeep, CO2, Renewable energy, Stellantis

Logility, Inc., a leader in prescriptive supply chain planning solutions, is pleased to announce Rubicon VLS was recently awarded responsibility for the network design and optimization of Stellantis LLC’s finished vehicle network in North America.

Key Points: 
  • Logility, Inc., a leader in prescriptive supply chain planning solutions, is pleased to announce Rubicon VLS was recently awarded responsibility for the network design and optimization of Stellantis LLC’s finished vehicle network in North America.
  • Rubicon VLS is a tech-enabled third-party logistics subsidiary of ICL, Inc.; a partner of Logility.
  • Using the Logility® Digital Supply Chain Platform, a web-native Network Optimization solution, the Rubicon VLS team will identify opportunities to improve reliability, increase consistency and drive efficiency throughout the Stellantis outbound supply chain.
  • “Logility’s Network Optimization tool will allow our team to leverage their deep knowledge of the Stellantis network to quickly analyse and find the most optimal routes and transport modes,” said Josh DelCorvo, Director of Rubicon VLS.

Inprentus wins contract to provide a VLS grating for the diagnostic spectrometer at the Shanghai Soft X-ray Free-Electron Laser (SSXFEL)

Retrieved on: 
Monday, June 19, 2023
SSRF, Radiation damage, Shanghai Synchrotron Radiation Facility, Light, Carbon, Louisiana Tech University College of Engineering and Science, Science, Astigmatism, VLS, Water, Biology, EUV, FEL, R, Microscope, Telescopic sight

CHAMPAIGN , Ill., June 19, 2023 /PRNewswire-PRWeb/ -- Shanghai Tech University has chosen Inprentus to provide a diffraction grating for the Shanghai Soft X-ray Free-Electron Laser (SSXFEL), the first X-ray free-electron laser user facility in China. Inprentus was selected for its unique capability to manufacture a blazed diffraction grating with varied line spacing (VLS) on a cylindrical, concave substrate. The grating will be one of the core elements used in the diagnostic spectrometer to provide high spectral resolution photon diagnostics of the FEL-II beamline.

Key Points: 
  • Shanghai Tech University has chosen Inprentus to provide a diffraction grating for the Shanghai Soft X-ray Free-Electron Laser (SSXFEL), the first X-ray free-electron laser user facility in China.
  • CHAMPAIGN , Ill., June 19, 2023 /PRNewswire-PRWeb/ -- Shanghai Tech University has chosen Inprentus to provide a diffraction grating for the Shanghai Soft X-ray Free-Electron Laser (SSXFEL), the first X-ray free-electron laser user facility in China.
  • Inprentus was selected for its unique capability to manufacture a blazed diffraction grating with varied line spacing (VLS) on a cylindrical, concave substrate.
  • The grating will be one of the core elements used in the diagnostic spectrometer to provide high spectral resolution photon diagnostics of the FEL-II beamline.